AbbVie and Neurocrine have announced the US approval of Orilissa, the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.
Read More
The US Food and Drug Administration has extended its review of AbbVie and Neurocrine’s experimental uterine pain drug elagolix by three months.
Read More
A second late-stage study assessing AbbVie and Neurocrine’s experimental drug elagolix in women with uterine fibroids has met its primary endpoint.
Read More
